19:48 , Aug 23, 2018 |  BC Extra  |  Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro, cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme activity...
20:47 , May 2, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A high throughput, nanomolar-scale chemical synthesis and affinity-ranking platform could enable rapid identification of drug compounds with high binding affinities for their target proteins. The robotics-based platform involves three steps: use of dimethyl...
22:24 , Apr 24, 2018 |  BC Extra  |  Tools & Techniques

Merck adds affinity optimization to nanoscale synthesis system

A Nature paper from Merck & Co. Inc. (NYSE:MRK) describes a nanoscale synthesis system that incorporates affinity ranking to enable simultaneous product synthesis and characterization of affinity to a target of interest, which could reduce...
22:18 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

BioMed Valley's ulixertinib leads to partial responses in Phase I for solid tumors

BioMed Valley Discoveries Inc. (Kansas City, Mo.) said twice-daily oral ulixertinib (BVD-523) at doses of ≥600 mg led to 14 partial responses in about 101 evaluable patients with advanced solid tumors in a two-part Phase...
01:18 , Dec 13, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived liver and bile duct cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by treating patient tumor samples with collagenase and deoxyribonuclease I (DNASE1) to...
02:08 , Jul 26, 2017 |  BC Extra  |  Company News

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to...
21:51 , Apr 19, 2017 |  BC Week In Review  |  Clinical News

KO-947: Ph I started

Kura began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV KO-947 in about 72 patients. Kura Oncology Inc. (NASDAQ:KURA), La Jolla, Calif.  Product: KO-947  Business: Cancer  Molecular target: MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1)  Description: Inhibitor of...
21:51 , Apr 19, 2017 |  BC Week In Review  |  Clinical News

KO-947: Ph I started

Kura began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV KO-947 in about 72 patients. Kura Oncology Inc. (NASDAQ:KURA), La Jolla, Calif.  Product: KO-947  Business: Cancer  Molecular target: MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1)  Description: Inhibitor of...
14:13 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Skin cancer Mouse studies suggest dual inhibition of MAP2K1/MAP2K2 or MAPK1/MAPK3 could help treat PTEN hamartoma tumor syndrome (PHTS), a type of skin hyperplasia that can become malignant. In a mouse model of PHTS, dual...